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Use of hormone replacement therapy and risk of venous  
thromboembolism: nested case-control studies using the  
QResearch and CPRD databases
Yana Vinogradova,1 Carol Coupland,1 Julia Hippisley-Cox1
ABSTRACT
Objective
To assess the association between risk of venous 
thromboembolism and use of different types of 
hormone replacement therapy.
Design
Two nested case-control studies.
setting
UK general practices contributing to the QResearch or 
Clinical Practice Research Datalink (CPRD) databases, 
and linked to hospital, mortality, and social 
deprivation data.
ParticiPants
80 396 women aged 40-79 with a primary diagnosis of 
venous thromboembolism between 1998 and 2017, 
matched by age, general practice, and index date to 
391 494 female controls.
Main OutcOMe Measures
Venous thromboembolism recorded on general 
practice, mortality, or hospital records. Odds ratios 
were adjusted for demographics, smoking status, 
alcohol consumption, comorbidities, recent medical 
events, and other prescribed drugs.
results
Overall, 5795 (7.2%) women who had venous 
thromboembolism and 21 670 (5.5%) controls had 
been exposed to hormone replacement therapy 
within 90 days before the index date. Of these two 
groups, 4915 (85%)and 16 938 (78%) women used 
oral therapy, respectively, which was associated 
with a significantly increased risk of venous 
thromboembolism compared with no exposure 
(adjusted odds ratio 1.58, 95% confidence interval 
1.52 to 1.64), for both oestrogen only preparations 
(1.40, 1.32 to 1.48) and combined preparations (1.73, 
1.65 to 1.81). Estradiolhad a lower risk than conjugated 
equine oestrogen for oestrogen only preparations 
(0.85, 0.76 to 0.95) and combined preparations (0.83, 
0.76 to 0.91). Compared with no exposure, conjugated 
equine oestrogen with medroxyprogesterone acetate 
had the highest risk (2.10, 1.92 to 2.31), and estradiol 
with dydrogesterone had the lowest risk (1.18, 0.98 to 
1.42). Transdermal preparations were not associated 
with risk of venous thromboembolism, which was 
consistent for different regimens (overall adjusted odds 
ratio 0.93, 95% confidence interval 0.87 to 1.01).
cOnclusiOns
In the present study, transdermal treatment was the 
safest type of hormone replacement therapy when 
risk of venous thromboembolism was assessed. 
Transdermal treatment appears to be underused, with 
the overwhelming preference still for oral preparations.
Introduction
Venous thromboembolism (VTE) is a rare but serious 
risk associated with hormone replacement therapy 
(HRT). HRT is used to prevent a range of symptoms 
experienced by many women during the menopause, 
such as hot flushes and night sweats. In 2015, in 
response to a halving of HRT use after two large studies1 2 
had raised concerns about the safety profile of HRT 
(including VTE risk), the National Institute for Health 
and Care Excellence (NICE) published its first guideline 
on diagnosis and management of menopausal 
symptoms in the United Kingdom.3 A central theme 
was the need to inform women of the risks and benefits 
of HRT so that they can make appropriate treatment 
choices; but the recommendations relate to overall 
use of HRT, distinguishing only between oral and 
transdermal preparations.3 The guideline recommends 
further research on the risks of HRT containing 
different types of progestogens in combination with 
oestrogen. The guideline also notes that the VTE 
risk appears greater for oral preparations than for 
transdermal treatment. The guideline is likely to result 
in an increase in HRT use in women with menopausal 
symptoms, increasing the need for detailed studies of 
the long term risks of different HRT regimens.
Oral HRT formulations can be oestrogen only 
(unopposed) using conjugated equine oestrogen or 
estradiol, or oestrogen combined with a progestogen 
(opposed). Progestogens in combined formulations 
WhAT IS AlReAdy knoWn on ThIS TopIC
Randomised controlled trials in women with menopausal symptoms who use 
hormone replacement therapy have demonstrated increased risks of venous 
thromboembolism compared with no exposure
The conclusions were based mostly on preparations of conjugated equine 
oestrogen with and without medroxyprogesterone acetate
Observational studies have reported increased risks associated with overall 
hormone replacement therapy, but were not sufficiently powered to provide 
detailed comparisons between different types of treatment
WhAT ThIS STudy AddS
This large study, based on routinely collected data from primary care 
environments, analysed a number of individual types of hormone replacement 
therapy; most oral preparations were found to be associated with increased 
venous thromboembolism risks
Conjugated equine oestrogen preparations, with and without 
medroxyprogesterone acetate, were associated with the highest risks
No increased risk of venous thromboembolism was found for transdermal 
preparations
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include medroxyprogesterone acetate or newer agents 
such as norgestrel, dydrogesterone, or drospirenone. 
Previous studies assessing the VTE risk associated with 
different HRT treatments either have not distinguished 
between the types of oestrogen or progestogen, or 
were powered to analyse only the most common 
preparations.4 5 Findings from randomised controlled 
trials summarised in a Cochrane systematic review4 
were based mainly on the Women’s Health Initiative trial 
of women in the United States, who were predominantly 
in relatively good health.6 The review reported that 
increased risk was associated with oestrogen only oral 
preparations, and with oral combinations of conjugated 
equine oestrogen and medroxyprogesterone acetate. 
Other preparations have become available in the past 
20 years and across other countries, but observational 
studies on these treatments, which have been 
summarised in a meta-analysis, did not have consistent 
definitions of outcome and were not sufficiently powered 
to investigate individual types of HRT.5 Therefore, there 
is insufficient information on VTE risk associated with 
specific HRT formulations for clinicians and women 
to make informed choices about treating menopausal 
symptoms.
Our case-control study, based on the general female 
population in the UK, aimed to assess the associations 
between VTE risk and all available types of HRT in the 
UK between 1998 and 2017. The study performed 
additional analyses of subgroups of women based on 
age and body mass index.
Methods
study design
Full details of the study design have been published 
elsewhere.7 In summary, we conducted nested case-
control studies using the two UK primary care research 
databases QResearch and Clinical Practice Research 
Datalink (CPRD) and included all practices, which had 
contributed data for at least a year. We identified two 
open cohorts of women aged 40-79 years and registered 
with study practices between January 1998 and February 
2017. We excluded women with previous records of VTE 
or with less than one year of medical records.
selection of cases and controls
For the QResearch database, we identified cases of 
incident VTE recorded between January 1998 and 
February 2017 in the general practice records, or in 
hospital admissions or mortality records. For the CPRD 
analysis, we identified cases by using only the general 
practice records. We used incidence density sampling 
for both databases to match each case to up to five 
controls from the same practice and by year of birth.8 
The first date of diagnosis of VTE for cases became the 
index date for matched controls.
exposure to hormone replacement therapy
We used HRT prescription information for the last year 
before the index date and included types of oestrogen 
and progestogen, dosage, and duration of exposure. 
We defined overall exposure to HRT as any exposure 
to oral or transdermal (patch, subcutaneous, or gel 
formulation) preparations containing estradiol. Oral 
and transdermal exposures were analysed separately. 
We identified a few treatments that included both 
tablets and patches; in such instances, the patient 
was considered to have been exposed to both oral 
and transdermal HRT. Exposure was categorised as 
recent (within 90 days before the index date), past 
(91-365 days), or no exposure. The study’s main focus 
was on recent exposure to HRT, because a previous 
study showed that past exposure is not associated 
with increased risk of VTE.9 All included women 
had records for the one year before the index date; 
therefore, if women had no HRT prescriptions in this 
period, it meant that they were not exposed in terms of 
this study definition.
We classified exposure based on the most recent HRT 
prescription in the 90 days before the index date. Oral 
HRT included oestrogen only preparations (conjugated 
equine oestrogen and estradiol) and combined 
preparations (oestrogen with medroxyprogesterone 
acetate, dydrogesterone, norethisterone acetate, 
norgestrel/levonorgestrel, or drospirenone). Because 
of low numbers of participants exposed to norgestrel/
levonorgestrel or to drospirenone, we analysed these 
preparations as one type of drug—that is, other 
progestogens structurally related to testosterone.10 
Transdermal HRT included oestrogen only and 
combined estradiol and we analysed this route of 
administration separately. We removed participants 
from the analysis if they had prescriptions for two 
different types of oestrogen or progestogen in the last 
90 days issued on the same date. A few women had 
switched to another HRT within the last 90 days, so we 
added a switch indicator to the analysis.
We also analysed different regimens—cyclical or 
continuous—overall and separately for preparations 
with a sufficient number of cases (estradiol combined 
with norethisterone, and estradiol combined with 
dydrogesterone).
The dose was categorised as low (≤0.625 mg for oral 
conjugated equine oestrogen, ≤1 mg for oral estradiol, 
≤50 μg for transdermal estradiol) or high. We assessed 
exposure duration in the year before the index date 
by adding up the days of prescriptions plus any 
periods between prescriptions of shorter than 90 days. 
Duration was categorised as short term (≤84 days) or 
long term (>84 days). No use of HRT in the past year 
was the reference category for all analyses.
Our analysis also included other preparations with 
oestrogen or progestogen that are used as topical 
(cream) or vaginal (pessaries) treatments. In addition, 
we included two other drugs that do not contain 
oestrogen: tibolone for menopausal symptoms and 
raloxifene for osteoporosis.
confounders
We adjusted the analyses for confounding factors, 
which might have influenced whether doctors 
prescribed HRT or what specific HRT treatment was 
chosen. These factors are listed in table 1 and include 
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lifestyle factors such as smoking status and body 
mass index, family history of VTE, comorbidities, 
and acute conditions associated with increased VTE 
risk.11 Comorbidities had to be recorded at any time 
before the index date, and included asthma, atrial 
fibrillation, cancer, cardiovascular disease, chronic 
obstructive pulmonary disease, chronic renal disease, 
coagulation disturbances, congestive cardiac failure, 
inflammatory bowel disease, rheumatoid arthritis, 
systemic lupus erythematosus, and varicose veins. We 
considered acute conditions to be confounders if they 
were recorded in the six months before the index date; 
these conditions were gall bladder surgery, hip fracture 
or hip replacement operation, pregnancy, respiratory 
infection, and urinary tract infection. The analysis also 
included hospital admissions between two and six 
months before the index date. Other drugs that could 
be prescribed to women using HRT were included, 
either as current use (within 90 days before the 
index date) or past use (91-365 days before the index 
date). These were antipsychotics, antidepressants 
(tricyclic, selective serotonin reuptake inhibitors, and 
others), aspirin, tamoxifen, oral contraceptives, and 
progestogen only preparations.
statistical analysis
We used conditional logistic regression adjusted for 
the confounders to estimate odds ratios and to assess 
associations between HRT exposure and VTE risk. We 
assumed missing values for body mass index, smoking 
status, and alcohol consumption were missing at 
random and used imputation by chained equations. 
We created 10 imputed datasets and the imputation 
model included all listed confounders, current and 
past exposure, and the case-control indicator. We 
combined the odds ratios from each imputed dataset 
using Rubin’s rule.12
We conducted analyses of QResearch and CPRD 
separately, but tried to keep the study designs as 
similar as possible (identical when data availability 
allowed). Adjusted estimates from the databases were 
combined by a meta-analysis technique. The findings 
were consistently similar between the databases; we 
did not expect or detect any heterogeneity. Therefore, 
we used a fixed effect model to combine the results 
of the two analyses, and we report only combined 
adjusted odds ratios in the text and figures. We present 
adjusted odds ratios for the separate QResearch and 
CPRD analyses in the tables and supplementary tables.
We used the number needed to harm to estimate the 
magnitude of VTE risk in women exposed to oral HRT13; 
this was based on the adjusted odds ratios from the 
combined analysis and the VTE rate in the unexposed 
population. We obtained this rate using CPRD data by 
following the cohort until the first prescription of HRT. 
Because exposure to HRT is highest in women aged 
55-64 and VTE risk increases with age, we calculated 
the overall risk and the risk by age. To account for 
multiple comparisons, we chose a 1% significance 
level. We calculated 95% confidence intervals to allow 
comparison with other studies. Stata version 15 was 
used for all analyses.
additional analyses
We ran three sensitivity analyses to address a number 
of assumptions. Firstly, to assess the assumption that 
previous use of anticoagulants was not related to an 
unrecorded VTE event, we ran an analysis excluding 
all women with previous exposure to anticoagulants. 
Secondly, we conducted a sensitivity analysis because 
of a difference in the data sources between QResearch 
and CPRD. All QResearch practices are linked to 
hospital admissions, mortality, and Townsend 
deprivation data whereas only 56% of CPRD practices 
(61% of included patients) are linked. For the main 
analysis, we used data from all the CPRD practices, 
but for this sensitivity analysis we only included 
linked CPRD practices. We also excluded participants 
with previous VTE events on hospital records from 
this second sensitivity analysis. Thirdly, to assess the 
plausibility of the missing at random assumption, we 
performed an analysis on women with complete data 
for body mass index, smoking status, and alcohol 
consumption.
For ease of comparisons with other studies, we 
conducted four additional analyses. Firstly, we ran an 
analysis on women with a VTE diagnosis supported 
by hospital admissions or mortality records, or with 
anticoagulant prescriptions six weeks before or after 
the VTE diagnosis. We used only practices with linked 
data for this analysis. Secondly, we ran an additional 
analysis on idiopathic participants who did not have 
any of the comorbidities or recent medical events 
associated with an increased risk of VTE. We also 
conducted two subgroup analyses using two clinically 
important variables to stratify risk: age (categories 
40-54, 55-64, 65-79 years), and body mass index 
(categories: not overweight or obese, <25; overweight, 
25-30; and obese, >30). These analyses investigated 
whether associations differed among the subgroups.
Patient and public involvement
This study was unfunded, so patient and public 
involvement initially envisaged in anticipation of 
funding was not possible. No patients were involved in 
setting the research question or the outcome measures, 
nor were they involved in developing plans for design 
or implementation of the study. No patients were asked 
to aid in interpreting or disseminating the results. 
There are no plans to disseminate the results of the 
research to the relevant patient community.
Results
We identified 52 137 cases from the QResearch 
database between 2 January 1998 and 5 February 2017 
(the latest available data linkage date) using general 
practice, hospital admissions, or mortality records. 
We identified 28 259 cases from the CPRD database 
between 2 January 1998 and 22 February 2017 using 
general practice records. Of the CPRD cases, 16 638 
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Qresearch cPrD
cases (n=52 137) controls (n=259 542) cases (n=28 259) controls (n=131 952)
Age: 
 Mean (SD) 63.8 (11.0) 63.8 (11.0) 63.8 (10.9) 64.0 (10.8)
 40-54 23.3 (12 128) 23.3 (60 484) 22.9 (6467) 22.3 (29 463)
 55-64 22.5 (11 721) 22.5 (58 392) 23.2 (6566) 23.2 (30 652)
 65-79 54.3 (28 288) 54.2 (140 666) 53.9 (15 226) 54.4 (71 837)
Mean (SD) years of records 9.3 (5.7) 9.4 (5.7) 9.4 (5.7) 10.5 (5.8)
Ethnicity: 
 Recorded 68.6 (35 766) 74.0 (192 107) 70.1 (19 799) 63.9 (84 293)
 White or not recorded 94.8 (49 435) 94.2 (244 422) 97.7 (27 600) 97.7 (128 854)
 Bangladeshi 0.2 (86) 0.3 (899) 0.0 (10) 0.0 (57)
 Black African 0.8 (409) 0.8 (2141) 0.3 (93) 0.3 (349)
 Caribbean 1.5 (777) 1.2 (3044) 0.5 (148) 0.4 (479)
 Chinese 0.1 (44) 0.2 (596) 0.0 (13) 0.1 (191)
 Indian 1.0 (518) 1.2 (2998) 0.4 (120) 0.5 (707)
 Other 0.9 (491) 1.0 (2667) 0.6 (170) 0.6 (750)
 Other Asian 0.3 (176) 0.6 (1473) 0.2 (47) 0.2 (323)
 Pakistani 0.4 (201) 0.5 (1302) 0.2 (58) 0.2 (242)
Townsend deprivation fifth*:
 Most affluent 18.7 (9756) 21.6 (56 152) 14.3 (4053) 15.7 (20 738)
 2 19.5 (10 187) 21.2 (55 110) 14.2 (4024) 14.9 (19 654)
 3 21.2 (11 043) 20.8 (54 101) 12.9 (3649) 12.6 (16 655)
 4 21.1 (11 020) 19.4 (50 290) 11.9 (3355) 10.7 (14 177)
 Most deprived 19.4 (10 131) 16.9 (43 889) 7.8 (2207) 6.7 (8905)
Body mass index:
 Recorded 86.4 (45 069) 85.7 (222 326) 90.0 (25 433) 87.5 (115 395)
 Mean (SD) 29.3 (6.4) 27.3 (5.5) 29.5 (6.8) 27.4 (5.6)
 15-24 23.8 (12 410) 33.4 (86 623) 24.9 (7040) 33.7 (44 414)
 25-29 27.3 (14 239) 29.3 (76 056) 29.7 (8405) 30.9 (40 770)
 ≥30 35.3 (18 420) 23.0 (59 647) 35.3 (9988) 22.9 (30 211)
Smoking status:
 Recorded 94.6 (49 316) 93.6 (242 821) 96.6 (27 291) 95.0 (125 306)
 None 41.4 (21 582) 44.6 (115 657) 55.9 (15 789) 59.2 (78 169)
 Former 36.9 (19 224) 34.1 (88 558) 24.2 (6838) 20.6 (27 193)
 Light (1-9 cigarettes/day) 8.8 (4588) 8.1 (21 067) 7.1 (2019) 6.4 (8447)
 Moderate (10-19) 4.4 (2299) 4.3 (11 156) 5.3 (1509) 5.4 (7060)
 Heavy (≥20) 3.1 (1623) 2.5 (6383) 4.0 (1136) 3.4 (4437)
Alcohol use:
 Recorded 85.4 (44 521) 84.6 (219 463) 87.6 (24 758) 86.4 (114 067)
 None 26.2 (13 645) 23.0 (59 656) 35.5 (10 034) 31.9 (42 044)
 Former use 12.6 (6571) 10.6 (27 564) 2.5 (706) 1.8 (2346)
 Trivial (<1 unit/day) 30.3 (15 809) 32.0 (83 003) 31.7 (8961) 32.4 (42 766)
 Light (1-2) 9.1 (4752) 11.1 (28 746) 12.6 (3560) 14.9 (19 696)
 Moderate (3-6) 6.5 (3378) 7.5 (19 346) 3.9 (1109) 4.3 (5632)
 Heavy (7-9) 0.4 (185) 0.3 (702) 0.9 (264) 0.8 (1099)
 Very heavy (≥10) 0.3 (181) 0.2 (446) 0.4 (124) 0.4 (484)
Chronic conditions: 55.6 (28 967) 35.3 (91 526) 57.9 (16 349) 36.7 (48 366)
 Asthma 15.4 (8041) 11.2 (28 980) 16.6 (4702) 12.0 (15 838)
 Atrial fibrillation 3.2 (1691) 2.5 (6569) 3.8 (1078) 2.6 (3461)
 Cancer 20.9 (10 873) 6.7 (17 419) 21.0 (5936) 6.9 (9069)
 Cardiovascular disease 12.6 (6558) 8.8 (22 791) 14.4 (4076) 10.0 (13 174)
 Chronic obstructive pulmonary disease 7.0 (3641) 3.8 (9925) 6.8 (1932) 3.8 (4956)
 Chronic renal disease 8.5 (4407) 5.4 (14 137) 8.5 (2401) 5.5 (7229)
 Congestive cardiac failure 2.9 (1507) 1.4 (3547) 3.3 (923) 1.6 (2048)
 Inflammatory bowel disease 1.7 (890) 1.0 (2506) 1.8 (501) 1.0 (1277)
 Rheumatoid arthritis 3.6 (1890) 2.0 (5171) 4.1 (1159) 2.0 (2679)
 Systemic lupus erythematosus 0.4 (220) 0.2 (429) 0.4 (120) 0.2 (238)
 Varicose veins 7.0 (3634) 5.2 (13 430) 7.7 (2173) 5.4 (7111)
Conditions and hospital admission in previous 
six months: 25.4 (13 250) 11.5 (29 813) 28.6 (8096) 11.4 (15 087)
 Gall bladder surgery 0.4 (229) 0.2 (392) 0.4 (109) 0.1 (181)
 Hip fracture/operation 3.3 (1743) 0.4 (961) 3.6 (1015) 0.3 (369)
 Hospital admission 6.6 (3460) 1.7 (4376) 7.7 (2185) 0.7 (873)
 Pregnancy 0.6 (320) 0.3 (854) 0.5 (132) 0.2 (302)
 Respiratory infection 12.6 (6571) 6.4 (16 672) 13.6 (3838) 7.2 (9488)
 Urinary infection 6.8 (3555) 3.7 (9477) 7.0 (1985) 3.7 (4857)
table 1 | characteristics of study population at or before the index date by database (Qresearch and cPrD). values are 
percentages (numbers) unless stated otherwise
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were also linked to hospital admissions and mortality 
data between 2 January 1998 and 31 March 2016; 
these cases were used in a sensitivity analysis (fig 1).
Table 1 presents the characteristics of the study 
participants across the databases. More than half of the 
women who had VTE were aged 65 or older; they were 
also more likely to have comorbidities than controls 
(overall, 56% v 36%), such as cancer (21% v 7%), 
cardiovascular disease (13% v 9%), or chronic renal 
disease (8% v 5%). Women who had VTE were more 
likely than controls to have recent medical events than 
controls (27% v 12%), such as respiratory or urinary 
infection (20% v 10%), hip fracture or operation (3.4% 
v 0.3%), or hospital admission (7% v 1%), and to use 
antidepressants (24% v 14%; table 1).
exposure (main analysis)
When combining CPRD and QResearch results, we 
found that 5795 (7.2%) women with VTE and 21 670 
(5.5%) controls were exposed to HRT in the 90 days 
before the index date. Figure 2 presents all available 
preparations and the numbers of exposed cases (for 
controls supplementary eFigure 1). In women exposed 
to HRT, 4915 (85%) cases and 16 938 (78%) controls 
used oral preparations, including 102 (1.8%) cases 
and 312 (1.4%) controls who also had transdermal 
preparations; 880 (14%) cases and 4731 (19%) 
controls used transdermal HRT only. Most of the 
transdermal preparations were prescribed in the form 
of patches (87% (n=858) in cases, 88% (n=4460) 
in controls), with only small proportions of women 
having subcutaneous and gel preparations (fig 2 and 
supplementary eFigure 1). 
Supplementary eTable 1 presents the number of 
study participants unexposed and exposed to oral 
and transdermal HRT across the confounding factors 
to highlight differences in prescribing. Women in 
the two younger age groups were more likely to have 
been exposed to HRT than women in the oldest group. 
Women exposed to HRT were less likely to be obese and 
have comorbidities such as cardiovascular disease, 
chronic renal disease, and cancer, but more likely to 
have used antidepressants. Women using transdermal 
HRT were more likely to have had oophorectomy or 
hysterectomy than women on oral HRT (73% (n=714) 
cases and 67% (n=3407) controls v 45% (n=2185) 
cases and 43% (n=7278) controls); these women 
were also slightly older and had more comorbidities 
(supplementary eTable 1).
Table 2 shows the number of study participants 
exposed to all types of HRT and adjusted odds 
ratios by database and for the combined analysis, 
compared with no exposure (unadjusted odds ratios 
are presented in supplementary eTable 2). Table 3 
presents information for direct comparisons between 
different types of HRT. Overall exposure to HRT in the 
past 90 days was associated with a 43% increased VTE 
risk (adjusted odds ratio 1.43, 95% confidence interval 
1.38 to 1.48; table 2) compared with no HRT use in the 
past year. Use of oral preparations was associated with 
a significantly increased VTE risk (1.58, 1.52 to 1.64), 
whereas transdermal HRT was not associated with 
VTE risk (0.93, 0.87 to 1.01; table 2). Compared with 
transdermal HRT, oral HRT was associated with a 70% 
increased risk of VTE (1.70, 1.56 to 1.85; table 3).
Oral oestrogen only and oral combined preparations 
were associated with increased VTE risk (adjusted 
odds ratio 1.40, 95% confidence interval 1.32 to 1.48, 
and 1.73, 1.65 to 1.81, respectively; table 2). Different 
types of oestrogen were associated with different risks. 
Oestrogen only preparations using conjugated equine 
oestrogen had higher VTE risks than preparations 
using estradiol (fig 3). Compared with oestrogen only 
conjugated equine oestrogen, use of oestrogen only 
estradiol was associated with a 15% reduction in VTE 
risk (0.85, 0.76 to 0.95; table 3). For combined oral 
preparations, the risks were significantly increased 
for conjugated equine oestrogen (1.91, 1.79 to 2.05) 
and estradiol preparations (1.59, 1.49 to 1.69; table 
2) compared with no HRT use in the past year. Direct 
comparison between the types of oestrogen showed 
a 17% lower risk for combined estradiol than for 
combined conjugated equine oestrogen (0.83, 0.76 to 
0.91; table 3).
For oral combined HRT, conjugated equine 
oestrogen with medroxyprogesterone acetate was 
associated with the highest risk of VTE (adjusted 
odds ratio 2.10, 95% confidence interval 1.92 to 
Qresearch cPrD
cases (n=52 137) controls (n=259 542) cases (n=28 259) controls (n=131 952)
Other characteristics:
 Early menopause 0.3 (151) 0.3 (792) 0.3 (79) 0.3 (334)
 Family history of VTE 0.0 (20) 0.0 (32) 0.2 (57) 0.1 (102)
 Oophorectomy/hysterectomy 28.1 (14 647) 23.7 (61 600) 30.7 (8682) 25.1 (33 068)
Other drugs in previous 90 days:
 Antipsychotics 3.4 (1750) 1.2 (3024) 3.3 (943) 1.0 (1377)
 Aspirin 13.4 (7010) 11.1 (28 743) 14.0 (3963) 10.8 (14 218)
 Combined oral contraceptives 0.8 (433) 0.3 (871) 1.4 (405) 0.9 (1216)
 Oral progestogen 0.8 (429) 0.4 (1157) 0.8 (222) 0.4 (539)
 Other antidepressants 3.7 (1918) 1.6 (4167) 3.2 (892) 1.5 (1949)
 Selective serotonin reuptake inhibitors 10.2 (5341) 6.5 (16 949) 4.2 (1186) 2.5 (3343)
 Tamoxifen 3.7 (1917) 1.2 (3077) 2.3 (642) 0.7 (869)
 Tricyclic antidepressants 9.8 (5129) 6.1 (15 757) 9.5 (2698) 5.5 (7264)
CPRD=Clinical Practice Research Datalink; SD=standard deviation; VTE=venous thromboembolism.
*Based on linked cases and controls.
table 1 | continued
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2.31), and estradiol with dydrogesterone with the 
lowest risk (1.18, 0.98 to 1.42; table 2 and fig 3). 
Compared with conjugated equine oestrogen with 
medroxyprogesterone, estradiol with dydrogesterone 
and estradiol with norethisterone were associated 
with 44% and 20% lower VTE risks, respectively 
(0.56, 0.45 to 0.69, P<0.001, and 0.80, 0.71 to 0.89, 
P<0.001, respectively; table 3).
Identified between 1998 and 2017, with at
least one year of data and no previous VTE
52 729 cases matched to 260 516 controls
Available for main analysis
52 137 cases matched to 259 542 controls
QResearch
Missing Townsend score
  Cases
  Controls
Conflicting prescriptions for recent exposure
  Cases
  Controls
Cases without controls
Controls without cases
86
486
10
24
496
464
Excluded
Included
Cases
Controls
Excluded
Cases with previous VTE
Controls with previous VTE
Cases without controls
Controls without cases
16 783
77 665
138
118
3
1437
Excluded
Cases
Controls with prescriptions
Controls without cases
3372
7014
16 233
Patients without previous anticoagulants prescriptions
48 765 cases matched to 236 295 controls
Available
Included
Cases with linked data and associated
  anticoagulant prescriptions
Cases with linked data only
Cases with associated anticoagulant prescriptions
  only
9592
10 545
19 493
39 630 cases matched to 197 310 controls
Available
Excluded
Cases
Controls with comorbidities or recent risk factors
  for VTE
Cases without controls
Controls without cases
33 876
107 181
329
95 614
Patients without chronic conditions or medical events
17 932 cases matched to 56 747 controls
Available
16 638 cases matched to 76 114 controls
Available
Identified between 1998 and 2017, with at
least one year of data and no previous VTE
28 262 cases matched to 131 976 controls
Available for main analysis
28 259 cases matched to 131 952 controls
CPRD
Conflicting prescriptions for recent exposure
  Cases
  Controls
Controls without cases
3
10
14
Excluded
Excluded
Cases
Controls
Cases without cases
Controls without cases
1500
2223
2
6811
Patients without previous anticoagulants prescriptions
26 757 cases matched to 121 918 controls
Available
Included
Cases with linked data and associated
  anticoagulant prescriptions
Cases with linked data only
Cases with associated anticoagulant prescriptions
  only
2274
1510
5912
9696 cases matched to 44 440 controls
Available
Excluded
Cases
Controls with comorbidities or recent risk factors
  for VTE
Cases without controls
Controls without cases
19 173
55 875
247
50 146
Patients without chronic conditions or medical events
Patients with linked data and Townsend score
8839 cases matched to 25 931 controls
Available
Cases with VTE diagnosis in hospital/mortality
records and/or anticoagulant prescription
Cases with VTE diagnosis in hospital/mortality
records and/or anticoagulant prescription
Fig 1 | Flow of included cases and controls for Qresearch and clinical Practice research Datalink (cPrD) analyses with numbers excluded and 
reasons for exclusion. vte=venous thromboembolism
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Overall, continuous and cyclical regimens for 
combined oral preparations were associated with an 
increased risk of VTE compared with no HRT use 
(adjusted odds ratio 1.55, 95% confidence interval 
1.44 to 1.66, and 1.88, 1.77 to 1.99, respectively; table 
2). However, not all combinations and age groups were 
equally covered. Younger women were more likely to 
be prescribed cyclical preparations and older women 
continuous preparations (supplementary eTable 3). 
Not all combined preparations were prescribed for 
cyclical and continuous regimens; conjugated equine 
oestrogen with medroxyprogesterone acetate was 
available mostly as a continuous regimen, whereas 
conjugated equine oestrogen with norgestrel was 
generally cyclical (fig 2 and supplementary eFigure 1). 
Only two preparations, estradiol with dydrogesterone 
and estradiol with norethisterone, had sufficient 
observations to assess the effect of the regimen. 
Neither cyclical nor continuous estradiol with 
dydrogesterone were associated with a statistically 
significantly increased VTE risk (1.21, 0.95 to 1.53, 
and 1.13, 0.84 to 1.53, respectively; table 2). Cyclical 
and continuous use of estradiol with norethisterone 
were associated with increased VTE risk compared 
with no HRT use (1.44, 1.28 to 1.63, and 1.80, 1.66 to 
1.95, respectively; table 2).
A large proportion of women using transdermal HRT 
had oestrogen only preparations (80% (n=781) in cases 
and 76% (n=3850) in controls (table 2). For combined 
preparations, norethisterone was the most common 
progestogen, with very low numbers for levonorgestrel 
and dydrogesterone, and most of the transdermal 
preparations had a lower dose of estradiol (fig 2). None 
of the transdermal preparations (oestrogen only or 
combined, low dose or high dose, combined cyclical 
or continuous) was associated with an increased VTE 
risk (table 2). Only a small proportion of women (about 
10%) had a short exposure of fewer than 84 days, and 
we did not detect any differences in risk compared with 
longer exposure (supplementary eTable 4).
Tibolone was used by 368 women with VTE and 
1859 controls, and its use was not associated with VTE 
risk (adjusted odds ratio 1.02, 95% confidence interval 
0.90 to 1.15; table 2). A small number of women (180 
cases and 631 controls) used raloxifene, which was 
associated with a significantly increased VTE risk 
(1.49, 1.24 to 1.79; table 2). Use of conjugated equine 
oestrogen cream or estradiol vaginal preparations was 
not associated with VTE risk (table 2). Past exposures 
to HRT in the 91-365 days before the index date were 
not significantly associated with increased VTE risk 
(supplementary eTable 5).
numbers needed to harm and excess risk of vte
The rate of VTE for the unexposed population based 
on the CPRD cohort was 16.0 per 10 000 women 
years. The rate differed among age groups: 9.0 per 
10 000 women years for age 40-54, 22.2 for age 55-
CEE MPA
Cyclical
Continuous
Low dose
32
708
>734
E2 norgestrel
Cyclical
Low dose
High dose
37
19
18
740
CEE norgestrel
Cyclical
Continuous
Low dose
High dose
607
7
410
204
Cyclical
Continuous
Low dose
High dose
94
58
106
46
Cyclical
Continuous
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High dose
614
E2 MPA
36
37
26
47
73 37
E2 dydrogesterone
152
Cyclical
Continuous
Low dose
High dose
392
923
380
935
E2 NEA
1315
Oral
2936
Transdermal
Patches
Subcutaneous
Gel
657
32
92
Transdermal Oral
1979
Oestrogen only
2700
Combined
3095
HRT
5795
E2 drospirenone
Continuous
Low dose
5
5
5
CEE
Low dose
High dose
771
437
781 201
1208
E2
Low dose
High dose
454
317
771
E2
Low dose
High dose
589
192
781
E2 NEA
Low dose
Cyclical
Continuous
181
79
102
E2 other
Low dose
Cyclical
Continuous
>14
9
11
181 20
Patches201
Fig 2 | Hormone replacement therapy (Hrt) preparations available in the uK and number of women with venous thromboembolism exposed to 
Hrt from Qresearch and clinical Practice research Datalink (cPrD) databases. some treatments comprised tablets and patches; 60 women in 
the oestrogen only group and 42 in the combined group were prescribed these treatments. cee=conjugated equine oestrogen; e2=estradiol; 
MPa=medroxyprogesterone acetate; nea=norethisterone acetate; other=dydrogesterone or levonorgestrel
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64, and 35.1 for age 65-79. Additional VTE cases were 
expected because of the increased VTE risk for users of 
most oral preparations (table 4).
For overall oral HRT use across all age groups, the 
number needed to harm was 1076 (95% confidence 
interval 974 to 1196) and the number of extra 
VTE cases was nine per 10 000 women years (95% 
confidence interval 8 to 10; table 4). The highest 
number of extra cases was for conjugated equine 
oestrogen with medroxyprogesterone acetate (18 per 
10 000 women years, 15 to 21), but this also increased 
with age (8 per 10 000, 5 to 13, for age 40-54; 37 per 
10 000, 26 to 50, for age 64-79; table 4).
additional analyses
The first sensitivity analysis run on cases and controls 
without previous anticoagulant prescriptions 
produced similar results to the main analysis, with a 
consistent difference among odds ratios of up to 0.02. 
In this analysis, estradiol with medroxyprogesterone 
acetate was associated with a statistically significantly 
increased VTE risk (fig 4 and supplementary eTable 6). 
The second sensitivity analysis used only hospital and 
mortality linked data for CPRD and produced similar 
results (supplementary eTable 7). The third sensitivity 
analysis run on cases and controls with complete data 
also gave similar findings (supplementary eTable 8). 
table 2 | exposure to different types of Hrt and adjusted odds ratios for venous thromboembolism risk by database and combined analysis
Qresearch cPrD
combined analysis 
Odds ratio (95% ci) P
no of cases/ 
controls adjusted odds ratio (95% ci)*
no of cases/ 
controls adjusted odds ratio (95% ci)*
Any HRT 3769/14 604 1.43 (1.37 to 1.50) 2026/7066 1.43 (1.35 to 1.52) 1.43 (1.38 to 1.48) <0.001
Oral preparations 3207/11 338 1.59 (1.52 to 1.67) 1708/5600 1.56 (1.46 to 1.67) 1.58 (1.52 to 1.64) <0.001
Oestrogen only: 1297/4568 1.42 (1.32 to 1.52) 682/2213 1.36 (1.23 to 1.50) 1.40 (1.32 to 1.48) <0.001
 CEE 786/2692 1.50 (1.37 to 1.64) 422/1308 1.48 (1.31 to 1.68) 1.49 (1.39 to 1.60) <0.001
 E2 511/1876 1.31 (1.17 to 1.46) 260/905 1.20 (1.02 to 1.40) 1.27 (1.16 to 1.39) <0.001
Combined with progestogen 1910/6770 1.73 (1.63 to 1.84) 1026/3387 1.72 (1.58 to 1.86) 1.73 (1.65 to 1.81) <0.001
CEE combined: 883/2870 1.90 (1.75 to 2.07) 471/1407 1.94 (1.72 to 2.18) 1.91 (1.79 to 2.05) <0.001
 CEE MPA 501/1438 2.22 (1.99 to 2.48) 239/732 1.87 (1.59 to 2.20) 2.10 (1.92 to 2.31) <0.001
 CEE norgestrel 382/1432 1.59 (1.41 to 1.80) 232/675 2.00 (1.70 to 2.36) 1.73 (1.57 to 1.91) <0.001
E2 combined: 1027/3900 1.61 (1.49 to 1.74) 555/1980 1.56 (1.40 to 1.74) 1.59 (1.49 to 1.69) <0.001
 E2 MPA 51/215 1.51 (1.09 to 2.09) 24/106 1.21 (0.74 to 1.96) 1.44 (1.09 to 1.89) 0.01
 E2 dydrogesterone 101/520 1.19 (0.95 to 1.50) 51/259 1.15 (0.82 to 1.60) 1.18 (0.98 to 1.42) 0.09
 E2 norethisterone 848/3043 1.69 (1.56 to 1.84) 467/1570 1.65 (1.46 to 1.86) 1.68 (1.57 to 1.80) <0.001
 E2 other progestogens† 27/122 1.40 (0.90 to 2.17) 13/45 1.65 (0.85 to 3.22) 1.42 (1.00 to 2.03) 0.05
Regimen: 
 Combined cyclical 1123/3606 1.96 (1.82 to 2.11) 411/1362 1.70 (1.50 to 1.92) 1.55 (1.44 to 1.66) <0.001
 Combined continuous 787/3164 1.48 (1.36 to 1.62) 825/2878 1.73 (1.56 to 1.92) 1.88 (1.77 to 1.99) <0.001
 E2 dydrogesterone cyclical 38/208 1.13 (0.78 to 1.63) 31/147 1.15 (0.75 to 1.76) 1.21 (0.95 to 1.53) 0.1
 E2 dydrogesterone continuous 63/312 1.23 (0.92 to 1.64) 20/112 1.14 (0.68 to 1.91) 1.13 (0.84 to 1.53) 0.4
 E2 norethisterone cyclical 585/1963 1.85 (1.67 to 2.04) 129/461 1.49 (1.20 to 1.85) 1.44 (1.28 to 1.63) <0.001
 E2 norethisterone continuous 263/1080 1.42 (1.23 to 1.65) 338/1109 1.72 (1.49 to 1.98) 1.80 (1.66 to 1.95) <0.001
Oral oestrogen dose: 
 CEE ≤0.625 mg 498/1934 1.37 (1.23 to 1.53) 273/891 1.47 (1.26 to 1.71) 1.40 (1.28 to 1.53) <0.001
 CEE >0.625 mg 288/758 1.81 (1.56 to 2.11) 149/417 1.51 (1.22 to 1.86) 1.71 (1.51 to 1.93) <0.001
 E2 ≤1 mg 303/1201 1.25 (1.09 to 1.43) 151/549 1.17 (0.96 to 1.44) 1.22 (1.09 to 1.37) <0.001
 E2 >1 mg 208/675 1.41 (1.19 to 1.67) 109/356 1.23 (0.97 to 1.57) 1.35 (1.18 to 1.55) <0.001
 CEE ≤0.625 mg norgestrel 262/1094 1.45 (1.26 to 1.68) 148/521 1.68 (1.38 to 2.06) 1.53 (1.36 to 1.72) <0.001
 CEE >0.625 mg norgestrel 120/338 2.06 (1.64 to 2.58) 84/154 3.06 (2.28 to 4.10) 2.38 (1.99 to 2.85) <0.001
 E2 ≤1 mg dydrogesterone 69/384 1.11 (0.85 to 1.46) 37/203 1.14 (0.78 to 1.66) 1.12 (0.90 to 1.40) 0.3
 E2 >1 mg dydrogesterone 32/136 1.40 (0.93 to 2.12) 14/56 1.18 (0.61 to 2.28) 1.34 (0.94 to 1.90) 0.1
 E2 ≤1 mg norethisterone 236/1082 1.39 (1.20 to 1.62) 144/586 1.37 (1.11 to 1.68) 1.38 (1.23 to 1.56) <0.001
 E2 >1 mg norethisterone 612/1961 1.85 (1.68 to 2.05) 323/984 1.81 (1.57 to 2.08) 1.84 (1.69 to 2.00) <0.001
Transdermal preparations: 640/3519 0.92 (0.84 to 1.00) 342/1525 0.97 (0.85 to 1.11) 0.93 (0.87 to 1.01) 0.07
 E2 only 503/2646 0.94 (0.85 to 1.04) 278/1204 0.99 (0.86 to 1.15) 0.96 (0.88 to 1.04) 0.3
 E2 combined 137/873 0.84 (0.69 to 1.01) 64/321 0.91 (0.67 to 1.23) 0.86 (0.73 to 1.01) 0.06
 Combined cyclical 71/462 0.84 (0.64 to 1.10) 22/124 0.91 (0.55 to 1.49) 0.85 (0.67 to 1.09) 0.2
 Combined continuous 66/411 0.84 (0.63 to 1.10) 42/197 0.89 (0.61 to 1.30) 0.86 (0.69 to 1.06) 0.2
Transdermal oestrogen dose:
 E2 ≤50 μg 377/2110 0.91 (0.81 to 1.02) 212/970 0.99 (0.84 to 1.16) 0.94 (0.85 to 1.03) 0.2
 E2 >50 μg 126/536 1.06 (0.86 to 1.31) 66/234 1.01 (0.75 to 1.38) 1.05 (0.88 to 1.24) 0.6
Other menopausal treatment:
 Tibolone 224/1218 0.99 (0.85 to 1.16) 144/641 1.07 (0.87 to 1.31) 1.02 (0.90 to 1.15) 0.8
 Raloxifene 114/419 1.48 (1.18 to 1.86) 66/212 1.51 (1.10 to 2.06) 1.49 (1.24 to 1.79) <0.001
 CEE cream 22/126 0.98 (0.61 to 1.57) 31/135 1.09 (0.71 to 1.69) 1.04 (0.76 to 1.43) 0.8
 E2 vaginal 87/545 0.84 (0.66 to 1.07) 204/1128 0.85 (0.71 to 1.00) 0.84 (0.73 to 0.97) 0.02
CEE=conjugated equine oestrogen; CPRD=Clinical Practice Research Datalink; E2=estradiol; HRT=hormone replacement therapy; MPA=medroxyprogesterone acetate.
*Odds ratios are based on cases and controls matched by age and practice and adjusted for smoking status, body mass index, family history of VTE, chronic and recent medical events, other 
drugs, and past exposures to hormones.
†Other progestogens include norgestrel/levonorgestrel and drospirenone.
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1.05 (0.88 to 1.24)
Different doses of oestrogen in HRT
Fig 3 | adjusted odds ratios for different types of hormone replacement therapy (Hrt) and different doses of 
oestrogen. Odds ratios are adjusted for current use of conjugated equine oestrogen cream, estradiol pessaries, oral 
progestogen, progesterone cream or vaginal preparations, past use of Hrt, smoking status, alcohol consumption, 
townsend deprivation fifth (Qresearch only), body mass index, comorbidities, recent events, current and past use 
of antidepressants, antipsychotics, aspirin, oral contraceptives, tamoxifen, and years of data. cases are matched to 
controls by age, general practice, and index date. *P<0.01
table 3 | Direct comparisons between different types of hormone replacement therapy (Hrt). values are adjusted odds 
ratios (95% confidence intervals)
Hrt comparison Qresearch cPrD combined analysis P
Oral v transdermal 1.74 (1.57 to 1.93) 1.61 (1.39 to 1.87) 1.70 (1.56 to 1.85) <0.001
E2 only v CEE only 0.87 (0.76 to 1.00) 0.81 (0.66 to 0.98) 0.85 (0.76 to 0.95) 0.005
E2 combined v CEE combined 0.85 (0.76 to 0.94) 0.81 (0.69 to 0.94) 0.83 (0.76 to 0.91) <0.001
CEE norgestrel v CEE MPA 0.72 (0.61 to 0.85) 1.07 (0.85 to 1.35) 0.87 (0.59 to 1.29) 0.5
E2 MPA v CEE MPA 0.70 (0.50 to 1.00) 0.64 (0.39 to 1.07) 0.68 (0.51 to 0.91) 0.01
E2 dydrogesterone v CEE MPA 0.54 (0.42 to 0.69) 0.61 (0.42 to 0.88) 0.56 (0.45 to 0.69) <0.001
E2 norethisterone v CEE MPA 0.76 (0.66 to 0.87) 0.88 (0.72 to 1.08) 0.80 (0.71 to 0.89) <0.001
E2 other v CEE MPA 0.60 (0.39 to 0.93) 0.88 (0.44 to 1.76) 0.67 (0.47 to 0.97) 0.03
CEE=conjugated equine oestrogen; CPRD=Clinical Practice Research Datalink; E2=estradiol; MPA=medroxyprogesterone acetate.
 o
n
 11 January 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k4810 on 9 January 2019. Downloaded from 
RESEARCH
10 doi: 10.1136/bmj.k4810 | BMJ 2019;364:k4810 | the bmj
The results from the analysis of cases with associated 
anticoagulant prescriptions or a VTE diagnosis 
from hospital or mortality records were similar; 
however, the reduced risks observed for women using 
transdermal therapy were statistically significant 
in the QResearch analysis, and consequently, in the 
combined analysis (fig 4 and supplementary eTable 
9). The subgroups for all these sensitivity analyses 
had similar HRT exposures to the main groups of 
cases and controls.
Selected women in the subgroups of idiopathic cases 
and matched controls had to be free of comorbidities; 
therefore, these subgroups were younger than the 
main sample. Women in the subgroups had higher 
exposure to HRT (9.0% v 7.2% for cases and 6.6% v 
5.5% for controls; table 2 and supplementary eTable 
10). The average number of matched controls per 
case was lower than in the main analysis (mean 3.09 
compared with 4.87). Findings were generally similar 
to the main analysis but with slightly wider confidence 
intervals. However, preparations with estradiol and 
medroxyprogesterone acetate were also associated 
with a statistically significant increased risk in VTE (fig 
4 and supplementary eTable 10).
Women in the age group 55-64 had the most 
HRT exposure (13.3% cases and 10.3% controls; 
supplementary eTable 12) compared with age groups 
40-54 (10.8% cases and 7.8% controls; supplementary 
eTable 11) and 65-79 (3.1% cases and 2.6% controls; 
supplementary eTable 13). The results were consistent 
across age subgroups and with the main analysis, but 
the odds ratios were slightly higher for the age group 
55-64. Overall exposure for oral HRT was associated 
with a significantly increased VTE risk in all age groups 
(adjusted odds ratio 1.52, 95% confidence interval 
1.42 to 1.63, for age 40-54; 1.69, 1.59 to 1.80, for age 
55-64; and 1.53, 1.42 to 1.65, for age 65-79; fig 5 and 
supplementary eTables 11-13).
Selecting women with VTE in a specific body mass 
index category and restricting matched controls 
to women in the same body mass index category 
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Fig 4 | adjusted odds ratios for different types of hormone replacement therapy (Hrt) for additional analyses. Odds ratios are adjusted for current 
use of conjugated equine oestrogen cream, estradiol pessaries, oral progestogen, progesterone cream or vaginal preparations, past use of Hrt, 
smoking status, alcohol consumption, townsend deprivation fifth (Qresearch only), body mass index, comorbidities, recent events, current and past 
use of antidepressants, antipsychotics, aspirin, oral contraceptives, tamoxifen, and years of data. cases are matched to controls by age, general 
practice, and index date. *P<0.01
table 4 | numbers needed to harm and excess risk of vte per 10 000 women for different types of Hrt over one year
numbers needed to harm over one year (95% ci) extra vte cases per 10 000 treated per year (95% ci)
all ages age 40-54 age 55-64 age 64-79 all ages age 40-54 age 55-64 age 64-79
Oral HRT 1076 (974 to 1196) 2037 (1688 to 2523) 655 (567 to 766) 536 (439 to 674) 9 (8 to 10) 5 (4 to 6) 15 (13 to 18) 19 (15 to 23)
CEE 1273 (1037 to 1613) 1797 (1274 to 2791) 1138 (786 to 1889) 676 (467 to 1117) 8 (6 to 10) 6 (4 to 8) 9 (5 to 13) 15 (9 to 21)
E2 2311 (1610 to 3841) 4011 (2332 to 10 720) NE NE 4 (3 to 6) 2 (1 to 4) NE NE
CEE MPA 567 (479 to 682) 1199 (783 to 2085) 334 (268 to 426) 268 (198 to 383) 18 (15 to 21) 8 (5 to 13) 30 (23 to 37) 37 (26 to 50)
CEE NG 859 (689 to 1104) 1178 (884 to 1651) 659 (452 to 1076) 382 (233 to 765) 12 (9 to 15) 8 (6 to 11) 15 (9 to 22) 26 (13 to 43)
E2 MPA 1428 (700 to 6779) NE NE NE 7 (1 to 14) NE NE NE
E2 NEA 924 (785 to 1105) 2162 (1535 to 3378) 455 (374 to 565) 485 (336 to 787) 11 (9 to 13) 5 (3 to 7) 22 (18 to 27) 21 (13 to 30)
CEE=conjugated equine oestrogen; E2=estradiol; HRT=hormone replacement therapy; MPA=medroxyprogesterone acetate; NE=no evidence; NEA=norethisterone acetate; NG=norgestrel.
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resulted in a reduced number of controls per case 
(not overweight or obese, mean 2.01; overweight, 
1.81; obese, 1.64). Women who were not overweight 
or obese had the highest exposure to HRT (8.8% 
cases and 7.0% controls; supplementary eTable 14) 
compared with those who were overweight (7.8% 
cases and 5.3% controls; supplementary eTable 
15) and obese (5.4% cases and 3.8% controls; 
supplementary eTable 16). The overall risk for oral 
HRT was the highest in the overweight subgroup 
(adjusted odds ratio 1.50, 95% confidence interval 
1.37 to 1.64, for women who were not overweight 
or obese; 1.79, 1.63 to 1.97, for women who were 
overweight; and 1.65, 1.48 to 1.84, for women who 
were obese; supplementary eTables 14-16). For the 
different types of HRT, the confidence intervals were 
wider but the results were consistent among all body 
mass index subgroups and with the main analysis (fig 
6 and supplementary eTables 14-16).
discussion
statement of principal findings
This study showed increased VTE risks for all oral HRT 
formulations, including combined and oestrogen only 
preparations. Overall, preparations with conjugated 
equine oestrogen were associated with higher risks 
than preparations using estradiol. Conjugated equine 
oestrogen with medroxyprogesterone acetate had the 
highest risk and estradiol with dydrogesterone had the 
lowest risk. Higher doses of oestrogen were associated 
with higher VTE risks. Transdermal HRT was not 
associated with any increased VTE risk and this finding 
was consistent for different regimens.
strengths and weaknesses of the study
This observational study of the UK general female 
population aged 40-79 used data from the two largest 
UK primary care databases, and routinely collected 
primary care data linked to secondary care data, 
and mortality records. The study matched cases 
and controls by age and general practice to account 
for differences in recording and prescribing across 
practices. Analyses adjusted for many confounding 
factors such as chronic and acute conditions, lifestyle 
factors, and social deprivation.
The study included all eligible cases, and additional 
analyses addressed assumptions. One sensitivity 
analysis in a subgroup of women with no previous use 
of anticoagulants reported similar results to the main 
analysis. This sensitivity analysis indicates that most of 
the excluded women had probably used anticoagulants 
because of atrial fibrillation or hip replacement 
operations rather than an earlier unrecorded VTE.
Records of test results confirming VTE diagnoses 
were not available to researchers. However, the 
sensitivity analysis, restricted to cases with subsequent 
prescriptions for anticoagulants or a VTE diagnosis from 
hospital or mortality records, supported the findings of 
the main analysis. In both the main analysis and the 
additional analysis, use of transdermal treatment was 
associated with a slight absolute reduction in VTE risk. 
There is no biological explanation for this protective 
effect; therefore, this small decrease might reflect some 
Oestrogen only oral HRT
    Conjugated equine oestrogen
    Estradiol
Combined oral HRT
  Conjugated equine oestrogen
    Medroxyprogesterone
    Norgestrel
  Estradiol
    Medroxyprogesterone
    Dydrogesterone
    Norethisterone
Transdermal HRT
    Estradiol
    Combined estradiol
Other menopausal therapy
    Tibolone
    Raloxifene
1.59 (1.38 to 1.83)*
1.26 (1.10 to 1.45)*
1.88 (1.51 to 2.35)*
1.90 (1.64 to 2.20)*
1.27 (0.82 to 1.96)
1.24 (0.95 to 1.62)
1.49 (1.31 to 1.69)*
1.01 (0.86 to 1.17)
0.90 (0.68 to 1.18)
1.33 (1.01 to 1.75)
#
0.5 1.0 1.5 2.5 3.02.0
Different
types of HRT
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Age 40-54
18 595 cases/89 945 controls
Odds ratio
(95% CI)
Age 55-64
18 284 cases/89 026 controls
Age 65-79
43 514 cases/212 503 controls
1.40 (1.24 to 1.57)*
1.22 (1.05 to 1.42)
2.35 (2.06 to 2.68)*
1.68 (1.42 to 2.00)*
1.68 (1.08 to 2.60)
1.14 (0.82 to 1.58)
1.99 (1.80 to 2.21)*
0.85 (0.74 to 0.98)
0.81 (0.63 to 1.06)
1.11 (0.91 to 1.34)
1.33 (0.89 to 1.97)
0.5 1.0 1.5 2.5 3.02.0
Odds ratio
(95% CI)
1.42 (1.26 to 1.61)*
1.10 (0.90 to 1.35)
2.06 (1.74 to 2.44)*
1.75 (1.37 to 2.22)*
1.82 (0.84 to 3.96)†
1.52 (0.92 to 2.53)
1.59 (1.36 to 1.85)*
0.96 (0.82 to 1.12)
1.00 (0.70 to 1.41)
0.79 (0.64 to 0.97)
1.46 (1.18 to 1.81)*
0.5 1.0 1.5 2.5 3.02.0
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Fig 5 | adjusted odds ratios for different types of hormone replacement therapy (Hrt) by age group. Odds ratios are adjusted for current use of 
conjugated equine oestrogen cream, estradiol pessaries, oral progestogen, progesterone cream or vaginal preparations, past use of Hrt, smoking 
status, alcohol consumption, townsend deprivation fifth (Qresearch only), body mass index, comorbidities, recent events, current and past use of 
antidepressants, antipsychotics, aspirin, oral contraceptives, tamoxifen, and years of data. cases are matched to controls by age, general practice, 
and index date. #=insufficient data. *P<0.01. †based on Qresearch analysis only
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residual confounding or possible indication bias. The 
finding was not statistically significant in the main 
analysis, but we reported a slightly greater, statistically 
significant decrease in the sensitivity analysis for the 
QResearch data. This is likely a spurious finding, 
possibly related to selection bias.
The study did not provide information about risks in 
patients with various conditions, but did separate VTE 
risks associated with HRT from those associated with 
chronic and acute conditions by running an additional 
analysis on patients without these conditions. 
The results proved similar and suggest a probable 
independent effect of HRT on VTE risk. Additional 
analyses based on age and body mass index provided 
extra information, but the results remained consistent 
across the categories and with the main results.
Although the analysis included all HRT preparations 
available in the UK, some preparations were not 
sufficiently prescribed to be assessed individually, 
such as estradiol with drospirenone, or estradiol with 
norgestrel or levonorgestrel. Frequently prescribed 
preparations, however, did have enough observations 
to study dosage effects. We were unable to assess 
differences in risks for women who had recently started 
or restarted HRT because the majority of women had 
been using HRT for more than 84 days.
The study also could not address several 
uncertainties. Exposure information was based on HRT 
prescriptions and not actual use. However, it is unlikely 
that cases and controls differed systematically in their 
adherence to HRT. Although we used all available 
information on confounding factors, data on important 
factors such as precise indications for HRT, age at 
menopause, and education level were not available. 
For a small but non-negligible proportion of women, 
data on smoking status, alcohol consumption, and 
body mass index were missing and had to be multiply 
imputed for the analysis. All of these limitations could 
have resulted in some residual confounding bias.
comparison with other studies
Several randomised controlled trials have assessed 
the safety of HRT, but most have not been sufficiently 
powered to assess VTE outcomes. Seventy per cent of 
data used in two recent meta-analyses4 14 were derived 
from two arms of one large trial on healthy American 
women (Women’s Health Initiative).6 The trial also 
concentrated on conjugated equine oestrogen based 
preparations most commonly used in the US. The 
Cochrane meta-analysis4 included VTE risks for up to 
two years of exposure to oestrogen only conjugated 
equine oestrogen (risk ratio 2.22, 95% confidence 
interval 1.12 to 4.39) and conjugated equine oestrogen 
with medroxyprogesterone acetate (2.98, 1.88 to 
4.71); the findings were slightly higher than those in 
our study. The other meta-analysis14 pooled oestrogen 
only preparations and combined oestrogen with 
progestogen preparations and reported increased VTE 
risks for both types of HRT (relative risk 1.43, 95% 
confidence interval 1.11 to 1.85; and 1.95, 1.54 to 
2.47). These results are similar to our findings for oral 
preparations.
Most of the observational studies did not distinguish 
between different types of HRT and assessed the 
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    Estradiol
Combined oral HRT
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    Medroxyprogesterone
    Norgestrel
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    Dydrogesterone
    Norethisterone
Transdermal HRT
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    Combined estradiol
Other menopausal therapy
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1.24 (1.04 to 1.49)
1.09 (0.86 to 1.38)
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1.83 (1.47 to 2.29)*
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1.22 (0.84 to 1.76)
1.63 (1.39 to 1.91)*
1.05 (0.85 to 1.29)
0.86 (0.62 to 1.20)
1.17 (0.87 to 1.57)
1.39 (0.94 to 2.06)
0.5 1.0 1.5 2.5 3.02.0
Different
types of HRT
Odds ratio
(95% CI)
Odds ratio
(95% CI)
BMI <25 kg/m2
17 114 cases/34 490 controls
Odds ratio
(95% CI)
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BMI >30 kg/m2
20 307 cases/33 338 controls
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1.45 (1.16 to 1.81)*
2.47 (1.96 to 3.12)*
1.73 (1.33 to 2.26)*
1.87 (1.01 to 3.46)
1.36 (0.84 to 2.21)
1.68 (1.41 to 2.00)*
0.87 (0.71 to 1.06)
1.23 (0.80 to 1.89)
0.82 (0.60 to 1.12)
1.19 (0.73 to 1.95)
0.5 1.0 1.5 2.5 3.02.0
Odds ratio
(95% CI)
1.44 (1.17 to 1.78)*
1.32 (1.06 to 1.65)
2.58 (1.92 to 3.46)*
1.54 (1.12 to 2.11)*
1.16 (0.51 to 2.64)
1.00 (0.58 to 1.72)
2.06 (1.68 to 2.54)*
1.02 (0.81 to 1.30)
0.73 (0.45 to 1.18)
1.22 (0.88 to 1.69)
1.37 (0.70 to 2.65)
0.5 1.0 1.5 2.5 3.02.0
Odds ratio
(95% CI)
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(95% CI)
Fig 6 | adjusted odds ratios for different types of hormone replacement therapy (Hrt) by body mass index (bMi). Odds ratios are adjusted for current 
use of conjugated equine oestrogen cream, estradiol pessaries, oral progestogen, progesterone cream or vaginal preparations, past use of Hrt, 
smoking status, alcohol consumption, townsend deprivation fifth (Qresearch only), body mass index, comorbidities, recent events, current and past 
use of antidepressants, antipsychotics, aspirin, oral contraceptives, tamoxifen, and years of data. cases are matched to controls by age, general 
practice, and index date. bMi=body mass index. *P<0.01
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overall risks associated with all formulations. Several 
studies had separated oral and transdermal use and 
reported higher risks for oral HRT.15-19 One meta-
analysis reported the combined findings of oral versus 
transdermal HRT (relative risk 1.63, 95% confidence 
interval 1.40 to 1.90).5 These results are in line with 
our findings (odds ratio for oral HRT v transdermal 
HRT 1.70, 95% confidence interval 1.56 to 1.85).
Some studies have assessed the risks associated with 
different oestrogen doses and reported higher risks 
with higher doses.18-20 One study compared cyclical 
use with continuous use and found higher risks 
associated with continuous use.19 Some studies based 
on the US population included the most frequently 
prescribed HRT, conjugated equine oestrogen with 
medroxyprogesterone, simply extrapolating the results 
to all synthetic progesterones.21 22 A US study extended 
the exposure to estradiol with medroxyprogesterone, 
but the study was not sufficiently powered to show 
increased VTE risk.20 Two French studies investigated 
VTE risks associated with different pharmacological 
classes of progestogens and found that pregnane 
progesterones including dydrogesterone and 
medroxyprogesterone acetate were not associated with 
increased VTE risk.16 17 However, these two studies 
were insufficiently powered and produced findings 
with wide confidence intervals.
A UK study, the Million Women Study, conducted 
between 1997 and 2002 and based on women aged 
50-64, included a range of preparations such as 
oral conjugated equine oestrogen, estradiol, and 
progestogens medroxyprogesterone, norethisterone, 
and norgestrel. Results for individual progestogens were, 
however, reported across both types of oestrogen and 
for different doses. The results, although less powered 
(2200 exposed cases), were similar to the findings from 
our study for oestrogen only HRT (relative risk 1.46, 
95% confidence interval 1.23 to 1.75, for conjugated 
equine oestrogen; and 1.45, 1.06 to 1.98, for estradiol); 
however, the study reported slightly higher VTE risks 
associated with combined HRT (2.07, 1.86 to 2.32).19
A Cochrane review summarised evidence on the 
side effects of tibolone and showed no association 
with VTE23; our results were in line with this finding. 
For increased VTE risk in raloxifene users, our 
observational study supported the results from a meta-
analysis based on 189 exposed cases in randomised 
controlled trials (odds ratio 1.62, 95% confidence 
interval 1.25 to 2.09).24
Meaning of the study: possible explanations and 
implications for clinicians and policy makers
This study has provided a more detailed picture of 
the VTE risks for different HRT preparations and can 
help clinicians and women make treatment choices. 
The study has shown that preparations based on 
conjugated equine oestrogen are associated with 
higher VTE risks than estradiol preparations, and this 
finding is consistent across age and body mass index 
categories. We did not expect to find an association 
between transdermal use and VTE risk because of the 
metabolic process,25 which has been confirmed in 
previous studies.16 19 26 However, our study showed 
that the vast majority of women using HRT continue 
to be prescribed oral preparations. When women with 
menopausal symptoms already have an increased VTE 
risk because of comorbidities or obesity, these women 
and their doctors should give greater consideration to 
transdermal HRT, in line with the NICE guideline.3
unanswered questions and future research
The HRT research recommendations from NICE raise 
concerns about VTE risk and about some cancers—in 
particular breast cancer—so a complementary detailed 
study of cancer risks is needed for a more complete 
picture. We are preparing such a study, based on the 
same data sources.
conclusion
This large observational study, based on the UK general 
female population aged 40-79, provides information 
on VTE risk in women taking different types of HRT. 
The study shows that conjugated equine oestrogen 
based oral preparations, combined or oestrogen only, 
are associated with higher VTE risk than estradiol 
based preparations. Higher oestrogen dose is also 
associated with higher VTE risk. However, transdermal 
HRT or tibolone, used much less frequently, are not 
associated with any increased VTE risk. Therefore, the 
study provides more information for clinicians and 
women about relative VTE risks and highlights that 
oral HRT is still the preferred choice over other forms 
of treatment with no associated VTE risks.
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